Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929120 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
A Phase 1 study of Interstitial Lung Disease and Connective Tissue Diseases, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03929120 is a Phase 1 study of Interstitial Lung Disease and Connective Tissue Diseases that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03929120, a Phase 1 study of Interstitial Lung Disease and Connective Tissue Diseases, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD).
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-11-05 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03929120
The ClinicalTrials.gov registry entry for NCT03929120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) is the first listed.
NCT03929120 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03929120 about?
NCT03929120 is a clinical study titled "Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)". Researchers are trying to find out more about the safety of a new treatment, Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) which is still experimental, for Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD).
What is the current status of trial NCT03929120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-11-05. Estimated completion is 2022-02-02.
What conditions does trial NCT03929120 study?
This clinical trial studies the following conditions: Interstitial Lung Disease, Connective Tissue Diseases.
What interventions are being tested in trial NCT03929120?
The interventions under investigation include: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03929120?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03929120 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
Feasibility of Semaglutide in Advanced Lung Disease
RECRUITING · Phase 1
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
RECRUITING · Phase 2
-
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
RECRUITING · Phase 3
-
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.